Related Experiment Video
Updated: Jan 29, 2026

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent
Simon P Hood1, Gemma A Foulds1, Heather Imrie2
1John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Abstract:
Background: Although immunotherapy has emerged as the "next generation" of cancer treatments, it has not yet been shown to be successful in the treatment of patients with prostate cancer, for whom therapeutic options remain limited to radiotherapy and androgen (hormone) deprivation therapy. Previous studies have shown that priming natural killer (NK) cells isolated from healthy individuals via co-incubation with CTV-1 cells derived from an acute lymphoblastic leukemia (ALL) enhances their cytotoxicity against human DU145 (metastatic) prostate cancer cells, but it remains unknown to what extent NK cells from patients with prostate cancer can be triggered to kill. Herein, we explore the phenotype of peripheral blood NK cells in patients with prostate cancer and compare the capacity of CTV-1 cell-mediated priming and IL-2 stimulation to trigger NK cell-mediated killing of the human PC3 (metastatic) prostate cancer cell line. Methods: The phenotype of resting, primed (co-incubation with CTV-1 cells for 17 h) and IL-2 activated (100 IU/ml IL-2 for 17 h) NK cells isolated from frozen-thawed peripheral blood mononuclear cell (PBMC) preparations from patients with benign disease (n = 6) and prostate cancer (n = 18) and their cytotoxicity against PC3 and K562 cells was determined by flow cytometry. Relationship(s) between NK cell phenotypic features and cytotoxic potential were interrogated using Spearman Rank correlation matrices. Results and Conclusions: NK cell priming and IL-2 activation of patient-derived NK cells resulted in similar levels of cytotoxicity, but distinct NK cell phenotypes. Importantly, the capacity of priming and IL-2 stimulation to trigger cytotoxicity was patient-dependent and mutually exclusive, in that NK cells from ~50% of patients preferentially responded to priming whereas NK cells from the remaining patients preferentially responded to cytokine stimulation. In addition to providing more insight into the biology of primed and cytokine-stimulated NK cells, this study supports the use of autologous NK cell-based immunotherapies for the treatment of prostate cancer. However, our findings also indicate that patients will need to be stratified according to their potential responsiveness to individual therapeutic approaches.
Insights
Natural killer (NK) cell immunotherapy shows promise for prostate cancer, but effectiveness varies by patient. NK cells can be activated by priming or IL-2, with individual responses dictating the best approach for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- Immunotherapy is a promising cancer treatment, but its efficacy in prostate cancer remains limited.
- Current prostate cancer treatments include radiotherapy and androgen deprivation therapy.
- Previous research indicated that priming natural killer (NK) cells enhances their cancer-killing ability.
Purpose of the Study:
- To investigate the phenotype of peripheral blood NK cells in prostate cancer patients.
- To compare the effectiveness of CTV-1 cell priming versus IL-2 stimulation in activating NK cell cytotoxicity against prostate cancer cells.
- To explore the patient-specific responses to different NK cell activation methods.
Main Methods:
- NK cells were isolated from peripheral blood mononuclear cells (PBMCs) of patients with benign conditions and prostate cancer.
- NK cells were subjected to three conditions: resting, CTV-1 cell priming, or IL-2 activation.
- Cytotoxicity against PC3 and K562 prostate cancer cell lines was assessed using flow cytometry, with phenotypic analysis and correlation studies.
Main Results:
- Both NK cell priming and IL-2 activation induced comparable levels of cytotoxicity but resulted in distinct NK cell phenotypes.
- The response to priming or IL-2 stimulation was patient-dependent and mutually exclusive.
- Approximately 50% of patients' NK cells responded better to priming, while the other 50% responded better to IL-2 stimulation.
Conclusions:
- NK cell priming and IL-2 activation offer viable strategies for enhancing NK cell-mediated killing of prostate cancer cells.
- Patient stratification based on NK cell responsiveness to priming or cytokine stimulation is crucial for personalized immunotherapy.
- This study supports the development of autologous NK cell-based immunotherapies for prostate cancer treatment.
Related Concept Videos
Co-activators and Co-repressors
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Activation Energy
tRNA Activation
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
Patient-centered Care

